[go: up one dir, main page]

WO2011067296A1 - Combinaison de huit allèles à risque associés à l'autisme - Google Patents

Combinaison de huit allèles à risque associés à l'autisme Download PDF

Info

Publication number
WO2011067296A1
WO2011067296A1 PCT/EP2010/068656 EP2010068656W WO2011067296A1 WO 2011067296 A1 WO2011067296 A1 WO 2011067296A1 EP 2010068656 W EP2010068656 W EP 2010068656W WO 2011067296 A1 WO2011067296 A1 WO 2011067296A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotide
seq
autism
detecting
snp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/068656
Other languages
English (en)
Inventor
Francis Rousseau
Jérôme CARAYOL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IntegraGen SA
Original Assignee
IntegraGen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IntegraGen SA filed Critical IntegraGen SA
Publication of WO2011067296A1 publication Critical patent/WO2011067296A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Definitions

  • the present invention relates to a method for detecting the presence or predisposition to autism, by detecting a combination of risk alleles in several genes simultaneously.
  • the Pervasive Developmental disorders are a heterogeneous group of disorders characterized by impairments in social interaction, deficits in verbal and nonverbal communication, restricted interests, and repetitive behaviors.
  • the disorders included in the spectrum are Pervasive Developmental disorder, Not Otherwise Specified (PDD-NOS), Autistic disorder, Childhood Disintegrative disorder, Asperger syndrome, and Rett syndrome.
  • Autism spectrum disorder represents three of the PDDs: Autistic disorder (AUT), Asperger syndrome (AS), and PDD-NOS.
  • Autistic Disorder comprises a severe set of cases from the Autism Spectrum Disorders (ASD).
  • the ASDs are currently diagnosed through behavioral tests (e.g. Autism Diagnostic Observation Schedule-Generic [ADOS-G]) or indirect, interview -based tests with third parties (e.g., Autism Diagnostic Interview— Revised [ADI-R]) (Lord et al. 1994).
  • ADOS-G Autism Diagnostic Observation Schedule-Generic
  • ADI-R Autism Diagnostic Interview— Revised
  • PDDs has a considerable genetic component, and siblings of autistic children have on average a recurrence risk of approximately 10%.
  • Monozygotic and dizygotic twin studies have shown that autism has a significant genetic component with monozygotic twin concordance rates as high as 91% if broad diagnostic criteria are applied.
  • PDDs does not follow a simple Mendelian inheritance pattern and this is thought to be due to the involvement of multiple genes (Veenstra-VanderWeele et al. 2004). Spontaneous mutations or rare inherited variants may help to explain etiology for a minority of cases, the inheritance pattern of common variants is likely central to disease risk in a majority of multiplex families.
  • PDDs is highly influenced by genetic factors.
  • Several genes associated with ASD have been identified by academic groups and through in-house research efforts at IntegraGen SA (IntegraGen).
  • IntegraGen SA IntegraGen SA
  • the contribution to disease risk of each individual gene identified is generally low, and the odds ratio per risk allele rarely is above 1.5.
  • the predictive power for each gene individually is too small to be of clinical utility in complex diseases.
  • the invention described here led to the identification and choice of a combination of specific polymorphisms within eight genes shown previously to be associated with ASD (PITX1, ATP2B2, EN2, CDH9/CDH10, MARK1, ITGB3, CNTNAP2, HOXA1).
  • the inventors tested association with clinical diagnosis in a subset of the AGRE cohort comprising about 900 cases (AGRE-IG). Comparison of odds ratios (ORs) for the entire sample and each of male and female cases separately suggests that the relationship between variation and clinical diagnosis at some loci is gender specific. Based on these data the inventors have developed a multigene autism risk assessment model. In particular, genotyping these eight genes can allow the estimation of a predictive value for the risk of developing ASD in yet non-affected siblings of affected individuals. The inventors showed that the predictive value that is obtained by detecting combinations of polymorphisms in these genes is superior to the predictive value obtained when observing alterations in each gene separately, demonstrating its clinical validity.
  • the clinical utility of this test resides in its ability to select at risk individuals for earlier down-stream diagnosis using psychological profiling tests (e.g. ADI-R or ADOS).
  • the test may also be used in affected individuals to accompany these profiling tests to substantiate the diagnosis for ASD and distinguish it from other psychiatric conditions.
  • the invention provides a method of detecting the presence of or predisposition to autism, preferably to an autism spectrum disorder or to an autistic disorder, in a subject, the method comprising detecting the presence of an alteration in the gene loci of at least ⁇ , ATP2B2, EN2, CDH9/CDH10, MARK1, ITGB3, CNTNAP2, and HOXA1 in a sample from said subject.
  • the alteration is a single nucleotide polymorphism.
  • ASD Pervasive Developmental disorders
  • AUT Autistic disorder
  • AS Asperger syndrome
  • PPD-NOS pervasive developmental disorders Not Otherwise Specified
  • AS is distinguished from ASD by the lack of a clinically significant delay in language development in the presence of the impaired social interaction and restricted repetitive behaviors, interests, and activities that characterize the autism- spectrum disorders (ASDs).
  • PPD-NOS PPD, not otherwise specified
  • AS autism- spectrum disorders
  • the invention provides diagnostic screening methods based on a monitoring of several genes in a subject.
  • the subject may be at early, pre- symptomatic stage, or late stage.
  • the subject may be any human male or female, preferably a child or a young adult.
  • the subject can be asymptomatic.
  • the method is particularly useful when the subject is a sibling of an individual with autism or an autism- spectrum disorder, i.e. an individual already diagnosed with autism or an autism spectrum disorder.
  • the likelihood that a sibling of a child with autism also develops autism or an autism-associated disorder is between 3 and 6 percent (Chakrabarti & Fombonne, 2001). This is approximately 20 times greater than the rate at which autism affects individuals who are not related to an affected individual.
  • the method of the invention can be performed at any age after birth and used to pre- screen individuals requiring further assessment with the ADI- R, shortening the time from diagnosis to intervention.
  • the diagnosis methods can be performed in vitro, ex vivo or in vivo, preferably in vitro or ex vivo. They use a sample from the subject.
  • the sample may be any biological sample derived from a subject, which contains nucleic acids. Examples of such samples include fluids, tissues, cell samples, organs, biopsies, etc. Most preferred samples are blood, plasma, saliva, jugal cells, urine, seminal fluid, etc.
  • the sample may be collected according to conventional techniques and used directly for diagnosis or stored.
  • the sample may be treated prior to performing the method, in order to render or improve availability of nucleic acids or polypeptides for testing. Treatments include, for instant, lysis (e.g., mechanical, physical, chemical, etc.), centrifugation, etc.
  • the nucleic acids may be pre -purified or enriched by conventional techniques, and/or reduced in complexity. Nucleic acids may also be treated with enzymes or other chemical or physical treatments to produce fragments thereof. Considering the high sensitivity of the claimed methods, very few amounts of sample are sufficient to perform the assay.
  • the sample is preferably contacted with reagents such as probes, or primers in order to assess the presence of an altered gene locus. Contacting may be performed in any suitable device, such as a plate, tube, well, glass, etc. In specific embodiments, the contacting is performed on a substrate coated with the reagent, such as a nucleic acid array.
  • the substrate may be a solid or semi-solid substrate such as any support comprising glass, plastic, nylon, paper, metal, polymers and the like.
  • the substrate may be of various forms and sizes, such as a slide, a membrane, a bead, a column, a gel, etc.
  • the contacting may be made under any condition suitable for a complex to be formed between the reagent and the nucleic acids of the sample.
  • the finding of a specific allele of PITX1, ATP2B2, EN2, CDH9/CDH10, MARK1, ITGB3, CNTNAP2, and HOXA1 DNA in the sample is indicative of the presence of a gene locus variant in the subject, which can be correlated to the presence, predisposition or stage of progression of autism, or an autism spectrum disorder.
  • a gene locus variant in the subject can be correlated to the presence, predisposition or stage of progression of autism, or an autism spectrum disorder.
  • an individual having a germ line mutation has an increased risk of developing autism, an autism spectrum disorder, or an autism-associated disorder.
  • the determination of the presence of an altered gene locus in a subject also allows the design of appropriate therapeutic intervention, which is more effective and customized. Also, this determination at the pre-symptomatic level allows a preventive regimen to be applied.
  • An alteration in a gene locus may be any form of mutation(s), deletion(s), rearrangement(s) and/or insertions in the coding and/or non-coding region of the locus, alone or in various combination(s). Alterations more specifically include point mutations or single nucleotide polymorphisms (SNP). Deletions may encompass any region of two or more residues in a coding or non-coding portion of the gene locus, such as from two residues up to the entire gene or locus. Typical deletions affect smaller regions, such as domains (introns) or repeated sequences or fragments of less than about 50 consecutive base pairs, although larger deletions may occur as well.
  • Insertions may encompass the addition of one or several residues in a coding or non-coding portion of the gene locus. Insertions may typically comprise an addition of between 1 and 50 base pairs in the gene locus. Rearrangement includes inversion of sequences.
  • the gene locus alteration may result in the creation of stop codons, frameshift mutations, amino acid substitutions, particular RNA splicing or processing, product instability, truncated polypeptide production, etc.
  • the alteration may result in the production of a polypeptide with altered function, stability, targeting or structure.
  • the alteration may also cause a reduction in protein expression or, alternatively, an increase in said production.
  • any SNP in linkage disequilibrium with a first SNP associated with autism or an associated disorder will be associated with this trait. Therefore, once the association has been demonstrated between a given SNP andautism or an associated disorder, the discovery of additional SNPs associated with this trait can be of great interest in order to increase the density of SNPs in this particular region.
  • Identification of additional SNPs in linkage disequilibrium with a given SNP involves: (a) amplifying a fragment from the genomic region comprising or surrounding a first SNP from a plurality of individuals; (b) identifying of second SNPs in the genomic region harboring or surrounding said first SNP; (c) conducting a linkage disequilibrium analysis between said first SNP and second SNPs; and (d) selecting said second SNPs as being in linkage disequilibrium with said first marker. Subcombinations comprising steps (b) and (c) are also contemplated. Methods to identify SNPs and to conduct linkage disequilibrium analysis can be carried out by the skilled person without undue experimentation by using well-known methods.
  • SNPs in linkage disequilibrium can also be used in the methods according to the present invention, and more particularly in the diagnostic methods according to the present invention.
  • PITX1, ATP2B2, EN2, CDH9/CDH10, MARK1, ITGB3, CNTNAP2, and HOXAl genes International patent application WO2006/003520 discloses that the ⁇ 1 gene on chromosome 5 and certain alleles thereof are related to susceptibility to autism.
  • the term "PITX1 gene” designates the pituitary homeobox transcription factor 1 gene on human chromosome 5q31.1, as well as variants, analogs and fragments thereof, including alleles thereof (e.g., germline mutations) which are related to susceptibility to autism and autism-associated disorders.
  • the PITX1 gene may also be referred to as paired-like homeodomain transcription factor pituitary homeobox 1, or PTX1.
  • ATP2B2 gene designates the ATPase, Ca++ transporting, plasma membrane 2 gene on human chromosome 3p25.3, as well as variants, analogs and fragments thereof, including alleles thereof (e.g., germline mutations) which are related to susceptibility to autism and autism-associated disorders.
  • the ATP2B2 gene may also be referred to as PMCA2. Association of ATP2B2 gene with autism was also reported in Hu et al. 2009.
  • rs6872664 ( ⁇ 1), rs35678 (ATP2B2), rs2292813 (SLC25A12), and rs 1861972 (EN2) showed significant association with autism with relative risks varying with the gene, the definition of autism, and the genotype (heterozygous or homozygous) (Philippi et al, 2007; WO2006/100608, Ramoz et al, 2004; Benayed et al, 2005).
  • CDH9/CDH10 refers to CDH9 or CDHIO gene locus, including the coding and the non-coding sequences, especially the non-coding sequences between the two genes.
  • MARK1 gene designates the MAP/microtubule affinity-regulating kinase 1 gene on human chromosome lq41, as well as variants, analogs and fragments thereof, including alleles thereof (e.g., germline mutations) which are related to susceptibility to autism and autism-associated disorders.
  • the MARK1 gene may also be referred to as MAP/microtubule affinity-regulating kinase, MARK, and KIAA1477.
  • the association of MARK1 with autism was also reported in Maussion et al. 2008, using a family based association study and an expression analysis.
  • ITGB3 gene encodes ITGB3 protein product is the integrin beta chain beta 3. Integrin beta 3 is found along with the alpha lib chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling. Association of ITGB3 with autism is reported in Weiss et al. 2006; Coutinho et al. 2007; Ma et al. 2009.
  • CNTNAP2 gene designates the contactin associated protein-like 2 gene on chromosome 7q35-q36, as well as variants, analogs and fragments thereof, including alleles thereof (e.g., germline mutations) which are related to susceptibility to obesity and associated disorders.
  • the CNTNAP2 gene may also be referred to as contactin-associated protein 2, cell recognition molecule (CASPR2), homolog of Drosophilia neurexin IV (NRXN4). Association of CNTNAP2 with autism was also reported in Alarcon et al.
  • HOXAl homeobox genes
  • A, B, C, and D the genes encoding the class of transcription factors
  • HOXAl is part of the A cluster on chromosome 7 and encodes a DNA-binding transcription factor which may regulate gene expression, morphogenesis, and differentiation.
  • the encoded protein may be involved in the placement of hindbrain segments in the proper location along the anterior-posterior axis during development. Association of HOXAl with autism was mentioned in Ingram et al. 2000; Conciatori et al. 2004; Sen et al. 2007.
  • SNPs single nucleotide polymorphisms
  • a subject of the invention is thus a method of detecting the presence of or predisposition to autism, or to an autism spectrum disorder in a subject, the method comprising detecting the combined presence of an alteration in the gene loci of at least PITX1, ATP2B2, EN2, CDH9, MARK1, ITGB3, CNTNAP2, and HOXAl in a sample from said subject.
  • the method comprises detecting the presence of a single nucleotide polymorphism (SNP) at position rs6872664 of PITXl (nucleotide 301 on SEQ ID NO: l), and/or detecting the presence of a single nucleotide polymorphism (SNP) at position rs2278556 of ATP2B2 (nucleotide 201 on SEQ ID NO:2), and/or detecting the presence of a single nucleotide polymorphism (SNP) at position rsl861972 of EN2 (nucleotide 301 on SEQ ID NO:3), and/or detecting the presence of a single nucleotide polymorphism (SNP) at position rs4307059 of CDH9/CDH10 (nucleotide 501 on SEQ ID NO:4) and/ordetecting the presence of a single nucleotide polymorphism (SNP) at position rsl24
  • the method comprises detecting the simultaneous presence of a SNP at position rs6872664 of PITXl (nucleotide 301 on SEQ ID NO: l), position rs2278556 of ATP2B2 (nucleotide 201 on SEQ ID NO:2), position rsl861972 of EN2 (nucleotide 301 on SEQ ID NO:3), position rs4307059 of CDH9/CDH10 (nucleotide 501 on SEQ ID NO:4), position rsl2410279 of MARK1 (nucleotide 201 on SEQ ID NO:5), position rs5918 of ITGB3 (nucleotide 401 on SEQ ID NO:6), position rs7794745 of CNTNAP2 (nucleotide 301 on SEQ ID NO:7), and position rsl0951154 of HOXA1 (nucleotide 521 on SEQ ID NO:
  • the presence of SNPs in linkage disequilibrium (LD) with the above- identified SNPs may be detected, in place of, or in addition to, said identified SNPs.
  • the method of the invention also referred to as "the test” thus preferably includes genotyping of all eight genes.
  • the test can be used to strengthen the diagnosis by confirming a known risk profile. In such case a negative test result does not invalidate the diagnosis for autism.
  • test can be used to establish a detailed risk profile for the non-affected sibling. Possible outcomes are:
  • the presence of an alteration in the gene locus may be detected by sequencing, selective hybridisation and/or selective amplification.
  • Sequencing can be carried out using techniques well known in the art, using automatic sequencers.
  • the sequencing may be performed on the complete genes or, more preferably, on specific domains thereof, typically those known or suspected to carry deleterious mutations or other alterations.
  • Amplification is based on the formation of specific hybrids between complementary nucleic acid sequences that serve to initiate nucleic acid reproduction.
  • Amplification may be performed according to various techniques known in the art, such as by polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA) and nucleic acid sequence based amplification (NASBA). These techniques can be performed using commercially available reagents and protocols. Preferred techniques use allele-specific PCR or PCR-SSCP. Amplification usually requires the use of specific nucleic acid primers, to initiate the reaction.
  • PCR polymerase chain reaction
  • LCR ligase chain reaction
  • SDA strand displacement amplification
  • NASBA nucleic acid sequence based amplification
  • Nucleic acid primers useful for amplifying sequences from the gene or locus are able to specifically hybridize with a portion of the gene locus that flank a target region of said locus, said target region being altered in certain subjects having autism, an autism spectrum disorder, or an autism-associated disorder
  • Hybridization detection methods are based on the formation of specific hybrids between complementary nucleic acid sequences that serve to detect nucleic acid sequence alteration(s).
  • a particular detection technique involves the use of a nucleic acid probe specific for wild type or altered gene, followed by the detection of the presence of a hybrid.
  • the probe may be in suspension or immobilized on a substrate or support (as in nucleic acid array or chips technologies).
  • the probe is typically labelled to facilitate detection of hybrids.
  • an alteration in the gene locus is determined by DNA chip analysis.
  • DNA chip or nucleic acid microarray consists of different nucleic acid probes that are chemically attached to a substrate, which can be a microchip, a glass slide or a microsphere-sized bead.
  • a microchip may be constituted of polymers, plastics, resins, polysaccharides, silica or silica-based materials, carbon, metals, inorganic glasses, or nitrocellulose.
  • Probes comprise nucleic acids such as cDNAs or oligonucleotides that may be about 10 to about 60 base pairs.
  • a sample from a test subject is labelled and contacted with the microarray in hybridization conditions, leading to the formation of complexes between target nucleic acids that are complementary to probe sequences attached to the microarray surface.
  • the presence of labelled hybridized complexes is then detected.
  • Many variants of the microarray hybridization technology are available to the man skilled in the art (see e.g. the review by Kidgell&Winzeler, 2005 or the review by Hoheisel, 2006).
  • the population consists in 483 informative families from a subset of AGRE repository ("VI.2 sample") with at least one affected (autism) children genotyped: 85 are trios including the parents and only the index case, 349 are families with two affected siblings, 44 are families with 3 affected siblings and 5 are families with 4 affected siblings. In these families, there is a total of 849 cases with the AUT among which 761 are genotyped together with their parents for all eight genes investigated (and a total of 935 with the ASD form of the disease among which 835 are genotyped) and used in the final model.
  • the male:female sex ratio is 3.69:1 in this sample with 668 males and 181 females affected (and 3.43:1 for broad autism with 724 males and 211 females).
  • Samples were genotyped using TaqMan allele discrimination assays supplied by Applied Biosystems (Foster City, CA, USA). Genotyping was performed on 384 well plates with 5 ng genomic DNA, 0.075 ⁇ of 20x SNP TaqMan Assay mix, 1.5 ⁇ of TaqMan Universal PCR Master Mix and 1.425 ⁇ of dH 2 0 in each well. PCR was then carried out using a 9700 Gene Amp PCR System (Applied Biosystems) with a profile of 95°C for 10 min and then 50 cycles at 92°C for 15 sec and 60°C for 90 sec. Plates were then subjected to end-point read in a 7900 Real-Time PCR System (Applied Biosystems).
  • Genotyping and data analysis were blinded to patient identification. Signal intensity plots and missing genotype frequencies were used for investigating genotyping quality. Poor clustering and missing fractions > 5% per SNP lead to regenotyping. Genotyping success rate was 97.4%.Parents were genotyped to check for Mendelian inconsistencies and to verify family relationships.
  • rs6872664 (PITX1) associates with autism in the whole sample with OR- 1.3;
  • rs4307059 (CDH9/CDH10) shows association on the whole sample and both genders; rsl2410279 (MARK1) shows "strong" sex effect without association on the overall sample;
  • CNTNAP2 CNTNAP2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention a pour objet une méthode de détection de la présence de l'autisme ou de la prédisposition à l'autisme, ou à un trouble du spectre autistique chez un sujet, la méthode comprenant la détection de la présence combinée d'une modification dans les loci génétiques d'au moins PITX1, ATP2B2, EN2, CDH9, MARK1, ITGB3, CNTNAP2, et HOXA1 dans un échantillon issu dudit sujet.
PCT/EP2010/068656 2009-12-01 2010-12-01 Combinaison de huit allèles à risque associés à l'autisme Ceased WO2011067296A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26539309P 2009-12-01 2009-12-01
US61/265,393 2009-12-01

Publications (1)

Publication Number Publication Date
WO2011067296A1 true WO2011067296A1 (fr) 2011-06-09

Family

ID=43618219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/068656 Ceased WO2011067296A1 (fr) 2009-12-01 2010-12-01 Combinaison de huit allèles à risque associés à l'autisme

Country Status (1)

Country Link
WO (1) WO2011067296A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109371115A (zh) * 2018-08-24 2019-02-22 山东德诺生物科技有限公司 用于检测rs5918的引物探针组及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228582B1 (en) 1997-06-17 2001-05-08 University Of Rochester Genetic polymorphisms which are associated with autism spectrum disorders
WO2005007812A2 (fr) 2003-07-03 2005-01-27 University Of Medicine And Dentistry Of New Jersey Genes utiles en tant qu'outils de diagnostic pour l'autisme
WO2005055807A2 (fr) * 2003-12-05 2005-06-23 Beatrice And Samuel A. Seaver Foundation Procedes et compositions pour recherche des predispositions a l'autisme
WO2006003520A2 (fr) 2004-07-01 2006-01-12 Integragen Gene de predisposition a l'autisme humain codant pour un facteur de transcription et ses utilisations
US20060141519A1 (en) * 2003-07-03 2006-06-29 Millonig James H Compositions and methods for diagnosing autism
WO2006087634A2 (fr) 2005-02-17 2006-08-24 Integragen Gene humain de susceptibilite a l'autisme codant pour une kinase et utilisations de celui-ci
WO2006087639A1 (fr) 2005-02-15 2006-08-24 Janssen Pharmaceutica N.V. Composition contenant de l'ocaperidone
WO2006100608A2 (fr) 2005-03-24 2006-09-28 Integragen Gene humain de susceptibilite a l'autisme codant une proteine transmembrane et ses utilisations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228582B1 (en) 1997-06-17 2001-05-08 University Of Rochester Genetic polymorphisms which are associated with autism spectrum disorders
WO2005007812A2 (fr) 2003-07-03 2005-01-27 University Of Medicine And Dentistry Of New Jersey Genes utiles en tant qu'outils de diagnostic pour l'autisme
US20060141519A1 (en) * 2003-07-03 2006-06-29 Millonig James H Compositions and methods for diagnosing autism
WO2005055807A2 (fr) * 2003-12-05 2005-06-23 Beatrice And Samuel A. Seaver Foundation Procedes et compositions pour recherche des predispositions a l'autisme
WO2006003520A2 (fr) 2004-07-01 2006-01-12 Integragen Gene de predisposition a l'autisme humain codant pour un facteur de transcription et ses utilisations
WO2006087639A1 (fr) 2005-02-15 2006-08-24 Janssen Pharmaceutica N.V. Composition contenant de l'ocaperidone
WO2006087634A2 (fr) 2005-02-17 2006-08-24 Integragen Gene humain de susceptibilite a l'autisme codant pour une kinase et utilisations de celui-ci
WO2006100608A2 (fr) 2005-03-24 2006-09-28 Integragen Gene humain de susceptibilite a l'autisme codant une proteine transmembrane et ses utilisations

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
ABRAHAMS B.S. ET AL.: "Advances in autism genetics: on the threshold of a new neurobiology", NATURE REVIEWS GENETICS, vol. 9, no. 5, May 2008 (2008-05-01), pages 341 - 355, XP002537731, ISSN: 1471-0056 *
AM J HUM GENET, vol. 82, pages 150 - 159
BENAYED R; GHARANI N; ROSSMAN I ET AL.: "Support for the Homeobox Transcription Factor Gene ENGRAILED 2 as an Autism Spectrum Disorder Susceptibility Locus", AM J HUM GENET, vol. 77, 2005, pages 851 - 68
CHAKRABARTI S; FOMBONNE E: "Pervasive developmental disorders in preschool children", JAMA, vol. 285, 2001, pages 3093 - 3099
CHEH MA; MILLONIG JH; ROSELLI LM; MING X; JACOBSEN E; KAMDAR S; WAGNER GC: "En2 knockout mice display neurobehavioral and neurochemical alterations relevant to autism spectrum disorder", BRAIN RES, vol. 1116, 2006, pages 166 - 176
CONCIATORI M; STODGELL CJ; HYMAN SL; O'BARA M; MILITERNI R; BRAVACCIO C; TRILLO S; MONTECCHI F; SCHNEIDER C; MELMED R: "Association between the HOXA1 A218G polymorphism and increased head circumference in patients with autism", BIOL PSYCHIATRY, vol. 55, 2004, pages 413 - 419
COUTINHO AM; SOUSA I; MARTINS M; CORREIA C; MORGADINHO T; BENTO C; MARQUES C; ATAIDE A; MIGUEL TS; MOORE JH: "Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels", HUM GENET, vol. 121, 2007, pages 243 - 256
CUTLER DJ; BRUNE CW; TESLOVICH TM; WEST K; IKEDA M; REA A; GUY M; LIN S; COOK EH; CHAKRAVARTI A: "A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism", AM J HUM GENET, vol. 82, 2008, pages 160 - 164
HOHEISEL, NATURE REVIEWS, GENETICS, vol. 7, 2006, pages 200 - 210
HU VW; SARACHANA T; KIM KS; NGUYEN A; KULKARNI S; STEINBERG ME; LUU T; LAI Y; LEE NH: "Gene expression profiling differentiates autism case-controls and phenotypic variants of autism spectrum disorders: evidence for circadian rhythm dysfunction in severe autism", AUTISM RES, vol. 2, 2009, pages 78 - 97
INGRAM JL; STODGELL CJ; HYMAN SL; FIGLEWICZ DA; WEITKAMP LR; RODIER PM: "Discovery of allelic variants of HOXA1 and HOXB1: genetic susceptibility to autism spectrum disorders", TERATOLOGY, vol. 62, 2000, pages 393 - 405
KIDGELL; WINZELER, CHROMOSOME RESEARCH, vol. 13, 2005, pages 225 - 235
LORD C; RUTTER M; LE COUTEUR A: "Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders", J AUTISM DEV DISORD, vol. 24, 1994, pages 659 - 685
MA DQ; RABIONET R; KONIDARI I; JAWORSKI J; CUKIER HN; WRIGHT HH; ABRAMSON RK; GILBERT JR; CUCCARO ML; PERICAK-VANCE MA: "Association and gene-gene interaction of SLC6A4 and ITGB3 in autism", AM J MED GENET B NEUROPSYCHIATR GENET, 2009
MAUSSION G; CARAYOL J; LEPAGNOL-BESTEL AM; TORES F; LOE-MIE Y; MILBRETA U; ROUSSEAU F; FONTAINE K; RENAUD J; MOALIC JM: "Convergent evidence identifying MAP/microtubule affinity-regulating kinase 1 (MARK1) as a susceptibility gene for autism", HUM MOL GENET, vol. 17, 2008, pages 2541 - 2551
MAUSSION GILLES ET AL: "Convergent evidence identifying MAP/microtubule affinity-regulating kinase 1 (MARK1) as a susceptibility gene for autism.", HUMAN MOLECULAR GENETICS, vol. 17, no. 16, 15 August 2008 (2008-08-15), pages 2541 - 2551, XP002629055, ISSN: 1460-2083 *
PEDIATR RES, vol. 65, no. 6, June 2009 (2009-06-01), pages 591 - 8
PHILIPPI A. ET AL.: "Association of autism with polymorphisms in the paired-like homeodomain transcription factor 1 (PITX1) on chromosome 5q31: a candidate gene analysis", BMC MEDICAL GENETICS, vol. 8, no. 1, 6 December 2007 (2007-12-06), BIOMED CENTRAL, LONDON, GB, pages 74, XP021034300, ISSN: 1471-2350 *
PHILIPPI A; TORES F; CARAYOL J; ROUSSEAU F; LETEXIER M; ROSCHMANN E; LINDENBAUM P; BENAJJOU A; FONTAINE K; VAZART C: "Association of autism with polymorphisms in the paired-like homeodomain transcription factor 1 (PITX1) on chromosome 5q31: a candidate gene analysis", BMC MED GENET, vol. 8, 2007, pages 74
POOT M; BEYER V; SCHWAAB I; DAMATOVA N; VAN'T SLOT R; PROTHERO J; HOLDER SE; HAAF T: "Disruption of CNTNAP2 and additional structural genome changes in a boy with speech delay and autism spectrum disorder", NEUROGENETICS, 2009
RAMOZ N. ET AL.: "Linkage and Association of the Mitochondrial Aspartate/Glutamate Carrier SLC25A12 Gene With Autism", AMERICAN JOURNAL OF PSYCHIATRY, vol. 161, no. 4, 1 April 2004 (2004-04-01), AMERICAN PSYCHIATRIC ASSOCIATION, WASHINGTON, DC, US, pages 662 - 669, XP002996520, ISSN: 0002-953X *
RAMOZ N; REICHERT JG; SMITH CJ ET AL.: "Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism", AM J PSYCHIATRY, vol. 161, 2004, pages 662 - 9
SEN B; SINHA S; AHMED S; GHOSH S; GANGOPADHYAY PK; USHA R: "Lack of association of HOXA1 and HOXB1 variants with autism in the Indian population", PSYCHIATR GENET, vol. 17, 2007, pages 1 1
VEENSTRA-VANDERWEELE J; COOK EH, JR: "Molecular genetics of autism spectrum disorder", MOL PSYCHIATRY, vol. 9, 2004, pages 819 - 832
WANG K; ZHANG H; MA D; BUCAN M; GLESSNER JT; ABRAHAMS BS; SALYAKINA D ET AL.: "Common genetic variants on 5pl4.1 associate with autism spectrum disorders", NATURE, vol. 459, 2009, pages 528 - 533
WANG L; JIA M; YUE W; TANG F; QU M; RUAN Y; LU T, ZHANG H; YAN H; LIU J; GUO Y: "Association of the ENGRAILED 2 (EN2) gene with autism in Chinese Han population", AM J MED GENET B NEUROPSYCHIATR GENET, vol. 147B, 2008, pages 434 - 438
WEISS LA; KOSOVA G; DELAHANTY RJ; JIANG L; COOK EH; OBER C; SUTCLIFFE JS: "Variation in ITGB3 is associated with whole-blood serotonin level and autism susceptibility", EUR J HUM GENET, vol. 14, 2006, pages 923 - 931
ZIEGLER A. ET AL.: "Combining information from multiple genes to evaluate clinical validity in nuclear families with affected offspring: autism spectrum disorder as example", GENETIC EPIDEMIOLOGY, vol. 32, no. 7, November 2008 (2008-11-01), & 17TH ANNUAL MEETING OF THE INTERNATIONAL-GENETIC-EPIDEMIOLOGY-SOCIETY; ST. LOUIS, MO, USA; SEPTEMBER 14 -16, 2008, pages 672 - 673, XP002537732, ISSN: 0741-0395 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109371115A (zh) * 2018-08-24 2019-02-22 山东德诺生物科技有限公司 用于检测rs5918的引物探针组及其应用

Similar Documents

Publication Publication Date Title
JP6078211B2 (ja) 自閉症および自閉症の表現型に関連する遺伝子変化ならびに自閉症の診断および治療に対するその使用方法
CA2865814A1 (fr) Test de genotypage pour evaluer le risque d'autisme
US20110086777A1 (en) Method for autism prediction
US20130137585A1 (en) New combination of eight risk alleles associated with autism
US20110091899A1 (en) Combination of risk alleles associated with autism
WO2016160600A1 (fr) Méthode d'identification du risque d'autisme
US20140336181A1 (en) Use of polymorphisms for identifying individuals at risk of developing autism
US20130317006A1 (en) Use of polymorphisms for identifying individuals at risk of developing autism
US7906283B2 (en) Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication
WO2011076783A2 (fr) Procédé d'évaluation d'un risque de trouble neuropsychiatrique transmissible
WO2011146788A2 (fr) Procédés d'estimation d'un risque de développement de méningo-encéphalite nécrosante
WO2008010082A2 (fr) Méthode diagnostique
WO2011067296A1 (fr) Combinaison de huit allèles à risque associés à l'autisme
US20140045717A1 (en) Single Nucleotide Polymorphism Biomarkers for Diagnosing Autism
KR101167934B1 (ko) Ｔｉｃａｍ1 유전자로부터 유래된 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 및 이를 이용한 자폐 스펙트럼 장애 분석방법
WO2014121180A1 (fr) Variantes génétiques chez des sujets atteints de maladie pulmonaire interstitielle
KR101167945B1 (ko) Ａｔｇ16ｌ1 유전자로부터 유래된 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 및 이를 이용한 자폐 스펙트럼 장애 분석방법
Gill et al. Overlap between ADHD and Autism–Clinical and Genetic Evidence
Mensah et al. Molecular analysis of a chromosome 4 inversion segregating in a large schizophrenia kindred from Hong Kong
KR101167942B1 (ko) Ａｌｇ12 유전자로부터 유래된 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 및 이를 이용한 자폐 스펙트럼 장애 분석방법
JP2006509521A (ja) ５−ヒドロキシトリプタミントランスポーター遺伝子多型
KR101167940B1 (ko) Ｆｍｎ2 유전자로부터 유래된 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 및 이를 이용한 자폐 스펙트럼 장애 분석방법
Toncheva Rare chromosomal deletions and duplications increase risk of schizophrenia
Roohi Identification of potential candidate genes in autism spectrum disorder
Ceroni Investigating the role of Copy Number Variants in Specific Language Impairment and identification of new candidate genes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10790373

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10790373

Country of ref document: EP

Kind code of ref document: A1